When Youyou heard this, she looked at the head teacher with her bright round eyes.
"The headmaster is so amazing! He actually grew a pumpkin!"
"No." Lu Xinghe looked a little shy, "It was planted by my friends and I."
Youyou shook her head, "No! It's because the headmaster took care of the little pumpkin that it grew so big!"
"Is pumpkin delicious?" Lingling asked curiously.
Youyou nodded quickly, "Pumpkin is delicious!"
Thinking of the sweet and sticky taste of pumpkin, she compared the size with her little round hands.
"The pumpkin is this big!"
"Wow!...
The content of this chapter is too short. Other websites may still be updating and will be automatically fixed later.
The following content is not relevant to this book.
"The myocardial autonomic cells artificially transformed by Professor Wang have been alive for a month!"
"Really? Is this project going to be a success?"
"It's hard to say. It's not certain how long the cells can survive with the new technology, and the clinical trial stage hasn't even started yet, but it looks promising."
"Yes, this kind of clinical trial involving genetic drugs is not easy to approve, right?"
In the corridor of the research institute, several researchers were chatting in their spare time, and what they were talking about was exactly what was worrying Chen Changan.
"So, the relevant departments are unwilling to approve our clinical trials?" Chen Changan frowned and asked with great dissatisfaction.
Guan Kou, who was standing next to him, explained with an equally serious expression: "After we submitted all the application materials, it was still rejected by the drug supervision and administration department. The reason given was that the risk was too high and there was not enough evidence to prove its safety."
Although clinical trials themselves are risky, the risks must be controlled to a certain extent, and not all trials can pass.
The relevant departments may only approve the review after the safety of the trial has been sufficiently proven. After all, clinical trials are conducted on patients, and these are human lives that cannot be handled carelessly.
As for the pacemaker project of the research center, there are still too many unknowns at present. Will the artificially transformed myocardial autonomic cells cause some irreversible changes to the genes?
How long is the life cycle of this cell extended?
Will there be any harm if these cells live in the human body for a long time? Will they cause genetic mutations?
What if this cell undergoes a genetic mutation?
The experimental pig No. 4 in the laboratory had only been implanted with new myocardial autonomic cells for a month. The data collected was too little and the safety was very questionable.
Therefore, the relevant departments directly rejected the application for clinical trials and required the research center to provide a complete biological test cycle safety certificate before applying for clinical trials.
In other words, we can only apply for clinical trials after the artificial myocardial autonomic cells in the body of experimental pig No. 4 have survived safely for one or two years without any genetic mutations, proving their safety.
This was the reason why Chen Changan looked embarrassed. If they really followed the requirements of the relevant departments, they would need at least one or two years before they could apply for clinical trials, and then the clinical trials would take another two to three years. It was unlikely that the biological pacemaker project would be available on the market within five years.
Moreover, this is a mandatory requirement. Since it concerns human lives, the relevant departments will not compromise!
But it's not that there is no good news at all.
After Guan Kou reported the difficulties of the biological pacemaker project team with a serious expression, his expression relaxed, and then he said with some joy: "Mr. Chen, although the clinical trial approval of the biological pacemaker project has not been passed, our artificial hematopoietic cell project has passed the clinical approval, and we can recruit volunteers for clinical trials!"
The artificial hematopoietic cell project is different from the biological pacemaker. The life cycle of a blood cell is only about 28 days, so it only takes 28 days to complete a complete biological experiment.
The research and development team led by Yun Heng has conducted two or three biological experiments using mice. They injected artificially induced red blood cells and platelets into mice that had lost blood. These two types of blood cells fully exerted their functions, and the effects were almost indistinguishable from the mice's own red blood cells and platelets.
Moreover, after the mice recovered, their blood cells continued to renew themselves normally, and the artificial blood cells injected by the project team were also replaced by new blood cells after 28 days.
All experiments have proved that the blood cells produced by artificially induced hematopoietic stem cell technology are exactly the same as normal blood cells and can be completely used as a substitute!
With sufficient experimental evidence, the artificial blood cell project was naturally easy to apply for clinical trials. After all, although this project also involves changes at the genetic level, it is only about modifying the genes of hematopoietic stem cells.
Because the artificial blood cells used by Chen Changan and his team are all mature blood cells~
The two special cells, red blood cells and platelets, which are transformed from hematopoietic stem cells, do not have a nucleus after they mature. That is to say, these two cells do not carry any genes or genetic factors in the mature body, so there is naturally no concern about gene mutations, and it is naturally easy to apply for the qualifications for clinical trials.
Overall, Chen Changan has mixed feelings. At least one of the two projects can be quickly monetized.
His focus could only be shifted to the induced hematopoietic stem cell project. As for the biological pacemaker project, he would put it on hold for the time being, and let Wang Jia's researchers prepare for a long-term battle.
Collect experimental data of experimental pig No. 4 on time.
Wait until the experimental data has been accumulated, and then try to reapply for clinical trials.
After the induced hematopoietic stem cell project obtained approval for clinical trials, the entire project team was divided into two parts again.
One part is led by researchers led by Yun Heng and the clinical team of the research center. They will bring materials and data and start rushing to three medical institutions designated by relevant departments to conduct clinical trials, recruit volunteers, extract human hematopoietic stem cells, carry out cultivation and induction work, and finally conduct clinical trials.
The other part is the research and development of hematopoietic equipment by researchers in the fields of mechanics, automation, chemical engineering, materials and other engineering disciplines led by Chen Changan.
Their next step is to master the manufacturing drawings and technical design points of a large blood-making machine provided by Chen Changan and try to carry out trial production.
This blood-making machine is a relatively large device, with a length, width and height of nearly 1.5 meters and a weight of nearly 2 tons. It occupies a large area and has a large volume. The production process requirements are also very sophisticated, and it requires very advanced machine tools to manufacture. There are tens of thousands of large and small parts.
It is absolutely impossible to manufacture these products relying on Ruikang Medical's factory alone. According to conservative estimates, at least thousands of upstream parts suppliers are needed!
Moreover, some of the parts may need to be imported from the Netherlands or Germany. Even Chen Changan cannot solve this problem because the manufacturing capacity of some high-end machine tools in China lags behind that of foreign countries. This is a limitation of the basic industry, and Chen Changan cannot change it.
After all, he can't build an industrial machine.
Fortunately, only a few parts need to be imported, and most parts can still be ordered from domestic machinery manufacturers.
Chen Changan planned to take the engineering researchers from the institute to try to understand the drawings and technology thoroughly and make a prototype to give it a try.
As for mass production, that will be the responsibility of Ruikang Medical and has nothing to do with the research center.
Chen Changan roughly calculated that the cost of one of these blood-making machines would be over a million, and the construction of the production line would require hundreds of millions of dollars, which is not a small amount of money.
Ruikang will only be able to invest money in the production of such large-scale equipment if it can get financing from Cheng. So don't even think about it for now.